Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | RGS12 | O14924 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407406 | 1.00 | ADRA2C (0.60) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL14350791 | 1.00 | ADRA2C (0.60) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL14393865 | 1.00 | ADRA2C (0.60) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL14350766 | 1.00 | ADRA2C (0.60) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL16164987 | 0.86 | ADRA2C (0.62) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL24736940 | 0.83 | ADRA2C (0.58) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL15159770 | 0.83 | ACACB (0.43) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL21051185 | 0.83 | ADRA2C (0.58) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL1863628 | 0.83 | ADRA2C (0.58) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL14338230 | 0.83 | ADRA2C (0.58) | ADRA2CCHRM2ADRA1ARGS12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894277-A | Preparation method and application of amide alkaloid EB-A extracted from equisetum hiemale | 河南中医药大学 | 2023-04-04 | — | — | CN | disclosed |
| US-7553816-B2 | p-amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7423116-B2 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7256257-B2 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20060229253-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS, INC. | 2006-10-12 | — | — | US | disclosed |
| US-7098308-B2 | Pentapetide containing a proline amino acid; cytotoxic agent | SEATTLE GENETICS, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-7091186-B2 | p-Amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1390393-A4 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | SEATTLE GENETICS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1442006-B1 | PREPARATION OF AMPHETAMINES FROM PHENYLPROPANOLAMINES | BOEHRINGER INGELHEIM CHEMICALS (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050113308-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS, INC. | 2005-05-26 | — | — | US | disclosed |
| US-20030130189-A1 | P-amidobenzylethers in drug delivery agents | SEAGEN INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030096743-A1 | p-Amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2003037843-A2 | PREPARATION OF AMPHETAMINES FROM PHENYLPROPANOLAMINES | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| WO-2003026577-A2 | P-AMIDOBENZYLETHERS IN DRUG DELIVERY AGENTS | SEATTLE GENETICS, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2002088172-A2 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | SEATTLE GENETICS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-6399828-B1 | ACYLATION OF PHENYLPROPANOLAMINE; CATALYTIC HYDROGENATION | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-4391980-A | FOR INVERSION OF CONFIGURATION OF OPTICALLY ACTIVE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1983-07-05 | — | — | US | disclosed |
| US-4294966-A | SALT FORMATION | CIBA-GEIGY CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
| EP-0007605-A1 | A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor | CIBA-GEIGY AG (CH) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113308-A1 | Pentapeptide compounds and uses related thereto | VIP, NGLY1, DNPEP | ADRA2C 4773/4885CHRM2 3769/4885ADRA1A 4622/4885 |
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | NGLY1, VIP, DNPEP | ADRA2C 4855/4885CHRM2 4825/4885ADRA1A 4824/4885 |
| US-20030130189-A1 | P-amidobenzylethers in drug delivery agents | ZYX, LPXN, NPBWR1 | ADRA2C 2672/4885CHRM2 2386/4885ADRA1A 1485/4885 |
| US-20060229253-A1 | Pentapeptide compounds and uses related thereto | VIP, NGLY1, DNPEP | ADRA2C 4657/4885CHRM2 4349/4885ADRA1A 4552/4885 |
| US-20030096743-A1 | p-Amidobenzylethers in drug delivery agents | ZYX, LPXN, NPBWR1 | ADRA2C 2544/4885CHRM2 2404/4885ADRA1A 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.